Literature DB >> 32712965

Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia.

Andrea Corbingi1, Idanna Innocenti1, Annamaria Tomasso2, Raffaella Pasquale3, Andrea Visentin4, Marzia Varettoni5, Elena Flospergher5, Francesco Autore1, Francesca Morelli6, Livio Trentin4, Gianluigi Reda3, Dimitar G Efremov7, Luca Laurenti1,2.   

Abstract

The relationship between chronic lymphocytic leukaemia (CLL) and qualitative/quantitative gammaglobulin abnormalities is well established. Nevertheless, in order to better understand this kind of connection, we examined 1505 patients with CLL and divided them into four subgroups on the basis of immunoglobulin (Ig) aberrations at diagnosis. A total of 73 (4·8%), 149 (10%), 200 (13·2%) and 1083 (72%) patients were identified with IgM monoclonal gammopathy (IgM/CLL), IgG monoclonal gammopathy (IgG/CLL), hypogammaglobulinaemia (hypo-γ) and normal Ig levels (γ-normal) respectively. IgM paraprotein was significantly associated with a more advanced Binet/Rai stage and del(17p)/TP53 mutation, while IgG abnormalities correlated with a higher occurrence of trisomy 12. Patients with any type of Ig abnormality had shorter treatment-free survival (TFS) but no significant impact affecting overall survival (OS) compared to those with normal Ig levels.
© 2020 British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  chronic lymphocytic leukemia; gamma globulin; monoclonal gammopathy

Year:  2020        PMID: 32712965     DOI: 10.1111/bjh.16975

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients.

Authors:  Namrata Singh; Sarah L Mott; Grerk Sutamtewagul; Ashley McCarthy; Susan L Slager; James R Cerhan; Zuhair Ballas; Brian K Link
Journal:  EJHaem       Date:  2020-09-01

2.  Case Report: Chronic Lymphocytic Leukemia With Recurrent Complement-Mediated Thrombotic Microangiopathy and C3 Glomerulonephritis.

Authors:  Tiantian Ma; Hui Wang; Tao Su; Suxia Wang
Journal:  Front Med (Lausanne)       Date:  2022-02-10

3.  Loss of AID exacerbates the malignant progression of CLL.

Authors:  Avery C Lee; Sai Ravi Pingali; Javier A Pinilla-Ibarz; Michael L Atchison; Constantinos Koumenis; Yair Argon; Andrei Thomas-Tikhonenko; Carl De Trez; Chih-Chi Andrew Hu; Chih-Hang Anthony Tang
Journal:  Leukemia       Date:  2022-08-30       Impact factor: 12.883

4.  Chronic Lymphocytic Leukemia-Induced Humoral Immunosuppression: A Systematic Review.

Authors:  Ewelina Grywalska; Monika Zaborek; Jakub Łyczba; Rafał Hrynkiewicz; Dominika Bębnowska; Rafał Becht; Barbara Sosnowska-Pasiarska; Jolanta Smok-Kalwat; Marcin Pasiarski; Stanisław Góźdź; Jacek Roliński; Paulina Niedźwiedzka-Rystwej
Journal:  Cells       Date:  2020-11-02       Impact factor: 6.600

Review 5.  From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance.

Authors:  Andrea Visentin; Stefano Pravato; Francesca Castellani; Marta Campagnolo; Francesco Angotzi; Chiara Adele Cavarretta; Alessandro Cellini; Valeria Ruocco; Alessandro Salvalaggio; Alessandra Tedeschi; Livio Trentin; Chiara Briani
Journal:  Cancers (Basel)       Date:  2022-03-18       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.